A carregar...
Expanding role of lenalidomide in hematologic malignancies
Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4427066/ https://ncbi.nlm.nih.gov/pubmed/25999761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S81310 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|